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Summary  
Background The increasing prevalence of overweight and obesity needs eﬀ ective approaches for weight loss in primary 
care and community settings. We compared weight loss with standard treatment in primary care with that achieved 
after referral by the primary care team to a commercial provider in the community.
Methods In this parallel group, non-blinded, randomised controlled trial, 772 overweight and obese adults were 
recruited by primary care practices in Australia, Germany, and the UK. Participants were randomly assigned with a 
computer-generated simple randomisation sequence to receive either 12 months of standard care as deﬁ ned by 
national treatment guidelines, or 12 months of free membership to a commercial programme (Weight Watchers), and 
followed up for 12 months. The primary outcome was weight change over 12 months. Analysis was by intention to 
treat (last observation carried forward [LOCF] and baseline observation carried forward [BOCF]) and in the population 
who completed the 12-month assessment. This trial is registered, number ISRCTN85485463.
Findings 377 participants were assigned to the commercial programme, of whom 230 (61%) completed the 12-month 
assessment; and 395 were assigned to standard care, of whom 214 (54%) completed the 12-month assessment. In all 
analyses, participants in the commercial programme group lost twice as much weight as did those in the standard 
care group. Mean weight change at 12 months was –5∙06 kg (SE 0·31) for those in the commercial programme versus 
–2∙25 kg (0·21) for those receiving standard care (adjusted diﬀ erence –2∙77 kg, 95% CI –3∙50 to –2∙03) with LOCF; 
–4∙06 kg (0·31) versus –1∙77 kg (0·19; adjusted diﬀ erence –2∙29 kg, –2∙99 to –1∙58) with BOCF; and –6∙65 kg (0·43) 
versus –3∙26 kg (0·33; adjusted diﬀ erence –3∙16 kg, –4∙23 to –2∙11) for those who completed the 12-month 
assessment. Participants reported no adverse events related to trial participation.
Interpretation Referral by a primary health-care professional to a commercial weight loss programme that provides 
regular weighing, advice about diet and physical activity, motivation, and group support can oﬀ er a clinically useful 
early intervention for weight management in overweight and obese people that can be delivered at large scale. 
Funding Weight Watchers International, through a grant to the UK Medical Research Council.
Introduction 
Obesity is a global health problem, with an estimated 
1 billion people worldwide overweight and more than 
300 million obese.1 Excess weight accounts for 44% of the 
global burden of diabetes, 23% of ischaemic heart disease, 
and 7–41% of some cancers.1 Weight loss of 5–10% is 
associated with clinically signiﬁ cant health beneﬁ ts, 
including a reduction in risk factors for diabetes and 
cardiovascular disease.2,3 Several inter ventions result in 
weight loss of 5–10%,4 but few can be delivered on a large 
scale. Eﬀ ective interventions to treat this problem in 
primary care or community settings are urgently needed.
Partnerships between primary care and commercial 
organisations have the potential to deliver weight 
management programmes on a large scale and at fairly 
low cost. Observational data lend support to the use of 
such an approach.5,6 However, few randomised controlled 
trials of commercial weight loss programmes have been 
done, and most assess self-selected participants or make 
comparisons with other self-help approaches.7–11 The 
eﬃ  cacy of commercial weight loss programmes has not 
been assessed in direct comparison with standard care in 
a primary health-care setting, with participants identiﬁ ed 
by the primary care provider. 
We compared the clinical eﬃ  cacy of primary care 
referral to a commercial programme with standard care 
by examination of the change in weight and associated 
risk factors at 12 months in overweight and obese adults. 
Methods
Study design and participants
We undertook a multicentre, randomised controlled trial 
with a parallel design. Participants were recruited from 
39 primary care practices in Germany, 70 practices in 
Australia, and six practices in the UK between Sept 10, 
2007, and Nov 28, 2008. People were screened for 
eligibility by a primary care provider in the UK, or ﬁ rst by 
the primary care provider and then by a member of the 
research team in Australia and Germany. Numbers of 
preliminary screenings in Germany were not recorded.
For more about the trial 
protocol see http://www.mrc-
hnr.cam.ac.uk/communications/
scienceunderthespotlight/
primary-care-referral-protocol
Articles
1486 www.thelancet.com   Vol 378   October 22, 2011
Eligible participants were adults (aged ≥18 years) with a 
body-mass index (BMI) of 27–35 kg/m² who had at least 
one additional risk factor for obesity-related disease. Risk 
factors included central adiposity (waist circumference 
>88 cm in women or >102 cm in men); type 2 diabetes 
without insulin treatment; family history of diabetes; 
previous gestational diabetes; impaired glucose tolerance 
or impaired fasting glycaemia, mild to moderate 
dyslipidaemia (deﬁ ned by national guidelines), or treat-
ment for dyslipidaemia; treatment for hyper tension; 
polycystic ovarian syndrome or infertility without apparent 
cause other than weight; lower-limb osteo arthritis; or 
abdominal hernia. People were excluded if they met any 
of the following criteria: weight loss of 5 kg or more in the 
previous 3 months; history of a clinically diagnosed eating 
disorder; orthopaedic limitations preventing participation 
in regular physical activity; untreated thyroid disease or 
more than one change in thyroid treatment in the previous 
6 months; receiving treatment with eﬀ ects on weight or 
appetite; gastro intestinal disorders; previous surgical 
procedure for weight loss; major surgery in the previous 
3 months; pregnancy or lactation; insulin-treated diabetes; 
diabetes diagnosis in the previous 6 months; glycated 
haemoglobin (HbA1c) of at least 75 mmol/mol (9∙0%); 
heart problems in the previous 3 months; uncontrolled 
hypertension; new prescription drug for a chronic 
disorder in the previous 3 months or change in dose in 
the previous 1 month; history or presence of cancer, with 
the exception of completely resected basal or squamous 
cell carcinoma if treatment completed 6 months before 
enrolment or if treatment was stable; or participation in 
another clinical trial in the previous 30 days.
This study received ethics approval from Nottingham 
Research Ethics Committee (UK), the ethical committee 
Figure 1: Trial proﬁ le
BMI=body-mass index. BOCF=baseline observation carried forward.
1010 participants assessed
for eligibility
238 excluded
134 not eligible
71 BMI >35 kg/m2
11 BMI <27 kg/m2
36 health or medical reasons
9 did not meet inclusion criteria
2 not willing to be randomly assigned
to commercial programme
1 not willing to be randomly assigned
to standard care
4 not willing or able to attend weekly 
weight loss meetings for 12 months
12 recruitment had ﬁnished
92 decided not to participate
772 randomised
377 allocated to commercial programme 395 allocated to standard care
147 withdrew
33 no reason given
4 adverse event or concomitant illness
8 pregnancy
17 personal reasons or other 
commitments
13 unhappy with intervention
1 diﬃculty attending assessment 
appointments
5 moved away
66 lost to follow-up or repeated 
non-attendance
377 analysed by BOCF
230 included in completers-only analysis
214 completed 12-month assessment
181 withdrew
47 no reason given
8 adverse event or concomitant illness
18 personal reasons or other 
commitments
12 unhappy with intervention
4 diﬃculty attending assessment 
appointments
7 moved away
85 lost to follow-up or repeated 
non-attendance
395 analysed by BOCF
214 included in completers-only analysis
230 completed 12-month assessment
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of the Faculty of Medicine of the Technische Universität 
München (Germany), and the ethics review committee 
(Royal Prince Alfred Hospital zone) of the Sydney South 
West Area Health Service (Australia). All patients 
provided written informed consent.
Randomisation and masking  
The randomisation sequence was computer generated 
with Stata (version 9.0) by APM and built into the 
database by the data manager, who was independent 
from the study team, and was stratiﬁ ed by country, sex, 
and diabetes status, with an upper limit of 50% of 
participants with diabetes. Participants were allocated in 
a 1:1 ratio to receive 12 months of free access to a 
commercial programme or 12 months of standard care, 
as deﬁ ned by national treatment guidelines in the three 
participating countries. Treatment allocation was 
concealed by use of an online database (Filemaker Pro 9, 
version 3). Because of the nature of the intervention and 
the primary care setting, participants and people 
assessing outcome measures were not masked to 
treatment assignments. 
Procedures  
Participants in the commercial programme group received 
free access to weekly community-based Weight Watchers 
meetings for 12 months. They were requested not to 
mention their participation in the study to the group 
leader or other attendees. This commercial programme 
promotes a hypoenergetic, balanced diet based on healthy-
eating principles, increased physical activity, and group 
support. Weight loss goals are self-selected with input 
from the group leader, and participants are encouraged to 
attend weekly meetings for a weigh-in and group 
discussion, behavioural counselling, and motivation. 
Participants were able to access internet-based systems to 
monitor their food intake, activity, and weight change; to 
participate in community discussion boards; and to access 
a library of information, recipes, and meal ideas.
Participants in the standard care group received 
weight loss advice from a primary care professional at 
their local general practitioner (GP) practice. Profes-
sionals delivering this intervention were provided with, 
and encouraged to use, Australian, German, and UK 
national clinical guidelines for treatment, and were 
made aware of information providing advice about 
weight loss.
Bodyweight, height, fat mass, waist circumference, and 
blood pressure were measured at baseline, and at 2, 4, 6, 
9, and 12 months. Clinical measurements were recorded 
at GP practices in the UK and at the research centre in 
Australia. In Germany, all measurements were recorded 
at GP practices except for fat mass, which was measured 
at the research centre.
In the UK and Australia, bodyweight (in light clothes 
without shoes) and fat mass were measured with a Tanita 
BC-418 segmental body composition analyser (Tanita 
Corporation of America, Arlington Heights, IL, USA). In 
Germany, weight was measured in GP practices with 
standard scales, and fat mass was measured at the 
research centre with the Tanita BC-418. Systolic and 
diastolic blood pressures were measured according to 
local standard operating procedures. At each assessment 
Commercial 
programme (n=377)
Standard care 
(n=395)
Sex
Women 330 (88%) 338 (86%)
Men 47 (12%) 57 (14%)
Age (years) 46·5 (13·5) 48·2 (12·2)
Weight (kg) 86·9 (11·6) 86·5 (11·5)
Height (m) 1·66 (0·1) 1·66 (0·1)
BMI (kg/m²) 31·5 (2·6) 31·3 (2·6)
Fat mass (kg) 33·3 (7·0) 32·9 (7·4)
Waist circumference (cm) 100 (9·2) 99·9 (9·3)
Systolic blood pressure 
(mm Hg)
124·7 (17·1) 124·2 (14·7)
Diastolic blood pressure 
(mm Hg)
78·2 (9·8) 79·1 (9·0)
Type 2 diabetes* 24 (6%) 27 (7%)
Data are number (%) or mean (SD). BMI=body-mass index. *Deﬁ ned by 
national guidelines.
Table 1: Baseline characteristics of participants according to 
treatment group
N Commercial 
programme
Standard care Adjusted diﬀ erence 
(95% CI)*
p value
Bodyweight (kg)
LOCF 772 –5·06 (0·31) –2·25 (0·21) –2·77 (–3·50 to –2·03) <0·0001
BOCF 772 –4·06 (0·31) –1·77 (0·19) –2·29 (–2·99 to –1·58) <0·0001
Completers 444 –6·65 (0·43) –3·26 (0·33) –3·16 (–4·23 to –2·11) <0·0001
Waist circumference (cm)
LOCF 760 –5·60 (0·37) –3·16 (0·28) –2·39 (–3·28 to –1·51) <0·0001
BOCF 760 –4·05 (0·35) –2·34 (0·26) –1·72 (–2·56 to –0·88)  0·0001
Completers 429 –6·86 (0·50) –4·34 (0·43) –2·36 (–3·65 to –1·08)  0·0004
Fat mass (kg)
LOCF 695 –4·23 (0·28) –1·85 (0·19) –2·32 (–2·96 to –1·68) <0·0001
BOCF 695 –3·21 (0·27) –1·34 (0·17) –1·84 (–2·45 to –1·23) <0·0001
Completers 397 –5·36 (0·38) –2·54 (0·30) –2·52 (–3·45 to –1·60) <0·0001
Systolic blood pressure (mm Hg)
LOCF 771 –2·37 (0·67) –1·50 (0·64) –0·71 (–2·35 to 0·92) 0·39
BOCF 771 –2·04 (0·56) –0·96 (0·53) –0·96 (–2·37 to 0·44) 0·18
Completers 441 –3·38 (0·92) –1·77 (0·96) –1·46 (–3·82 to 0·89) 0·22
Diastolic blood pressure (mm Hg)
LOCF 771 –1·61 (0·44) –1·29 (0·41) –0·64 (–1·73 to 0·45) 0·25
BOCF 771 –1·41 (0·36) –0·77 (0·35) –0·88 (–1·82 to 0·05) 0·07
Completers 441 –2·34 (0·59) –1·42 (0·65) –1·40 (–2·95 to 0·15) 0·08
LOCF=last observation carried forward. BOCF=baseline observation carried forward. *Adjusted for baseline observation 
and country. 
Table 2: Changes in clinical outcomes (mean; SE) between baseline and 12 months by treatment group 
(with analysis by LOCF, BOCF, and in those who completed the 12-month assessment) 
For Australian guidelines for 
obesity treatment see http://
www.health.gov.au/internet/
main/publishing.nsf/Content/
obesityguidelines-index.htm
For German guidelines for 
obesity treatment see http://
www.dge.de
For UK guidelines for obesity 
treatment see http://www.nice.
org.uk/CG043
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appointment, participants self-reported the number of 
appointments with their health-care provider or the 
number of commercial programme meetings that they 
had attended since the last assessment.
Fasting blood samples were taken to measure glucose, 
insulin, and lipid proﬁ le at baseline, and at 6 and 
12 months at either a research centre (Australia), GP 
practice (Germany), or biochemistry department at a 
local hospital (UK). HbA1c was measured at baseline; in 
patients with diabetes and impaired glucose tolerance, 
HbA1c was also measured at 6 and 12 months. Biochemical 
analyses were done locally in each country according to 
standardised methods (webappendix p 1).
The primary outcome was weight change from 
baseline to 12 months. Secondary outcomes were 
changes in fat mass, waist circumference, blood 
pressure, and bio markers of cardiovascular risk. Self-
reported data were recorded for dietary intake (4-day 
food diary), eating behaviour (three factor eating 
questionnaire R-2112), physical activity (7-day pedometer 
record, international physical activity questionnaire13), 
and quality of life (impact of weight on quality of life-
lite14), which will be analysed and published separately. 
Self-reported data for drug use will be used with 
additional data sources (including session attendance) 
in future cost-eﬀ ectiveness analyses. DNA samples 
were obtained for genetic analyses, and these data are 
being analysed to examine the genetic variations that 
could modify the extent of weight loss and improvements 
in cardiovascular risk factors. The protocol for this 
study was amended to include follow-up assessments at 
18 and 24 months, and results will be published after 
data analysis.
Statistical analysis  
We calculated that 804 patients needed to be recruited in 
the three countries to have 90% power at a 5% signiﬁ -
cance level to detect a diﬀ erence of 1∙9 kg in the primary 
outcome between the treatment groups, assuming an 
SD of 8 kg. With allowance for a drop-out of 50% of 
patients, this sample size would be suﬃ  cient to detect a 
diﬀ er ence in weight change of 2∙6 kg in an analysis of 
only patients who completed the study, with 90% power 
at a 5% signiﬁ cance level. 
The primary outcome was analysed by intention to 
treat, including all randomised participants, with last 
observation carried forward (LOCF) for missing data. 
Weight change at 12 months was analysed by use of 
linear regression with ﬁ xed eﬀ ects for continuous 
normal data; intervention group (commercial 
programme vs standard care), country (Australia, 
Germany, and the UK), and baseline measure ment were 
used as the ﬁ xed eﬀ ects. No country-by-treatment 
interactions were identiﬁ ed (p>0∙10), so we have 
reported ﬁ ndings for the pooled analysis. Mean changes 
are presented as mean (SE), with 95% CIs unless 
otherwise speciﬁ ed.
To maximise the comparability of our data with that 
in other studies, weight change was also analysed by 
use of baseline observation carried forward (BOCF), 
and in the population who completed the 12-month 
assessment (completers only). These analyses used the 
same ﬁ xed eﬀ ects model as in the LOCF analysis. 
12-month changes in biomarkers of cardiovascular risk 
were analysed by the same regression-based methods. 
We also calculated the percentage of randomised 
participants and those completing the 12-month 
assessment who achieved at least 5% and at least 10% 
weight loss. Odds ratios for percentage weight change 
were analysed with logistic regression. All analyses 
were done with STATA (version 11.0). 
This trial is registered, number ISRCTN85485463.
Figure 2: Change in weight during 12 months of treatment
Data are mean (SE). All measured weights are included at each timepoint. 
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Role of the funding source  
The commercial programme intervention was delivered 
by an employee of the sponsor, but the sponsor had no 
role in the study design, data collection, data analysis, 
data interpretation, or writing of the report. The authors 
had full access to all the data in the study, and the 
corresponding author had ﬁ nal responsibility for the 
decision to submit for publication.
Results  
Figure 1 shows the trial proﬁ le. 1010 partici pants were 
screened for eligibility, of whom 134 were not eligible, 
12 were screened after recruitment had ended, and 
92 chose not to participate. The remaining 772 participants 
(268 Germany, 268 Australia, 236 UK) entered the trial 
and completed a baseline assessment (ﬁ gure 1). 
Demographic and clinical characteristics of participants 
were well balanced across treatment groups (table 1), 
and country was the only factor used in adjusted 
analyses.
In all analyses, both treatment groups lost weight but 
mean 12-month weight loss was signiﬁ cantly greater for 
participants in the commercial programme than for 
those in the standard care group (table 2). Figure 2 shows 
the weight trajectories of the two treatment groups with 
all measured weights at each timepoint.
Participants assigned to the commercial pro gramme 
had increased odds of losing 5% or more 
(odds ratio [OR] 3∙0, 95% CI 2∙0–4∙4) and 10% or more 
(3∙2, 2∙0–5∙3) initial weight at 12 months than did those 
assigned to standard care. Similarly, participants who 
completed the 12-month assessment and were assigned 
to the commercial programme also had increased odds of 
losing 5% or more (2∙9, 2∙1–3∙9) and 10% or more 
(3∙5, 2∙3–5∙4) initial weight at 12 months than did 
those assigned to standard care. Figure 3 shows the 
percentages of participants who lost 5% or more and 10% 
or more bodyweight. 
The greater weight loss in participants assigned to the 
commercial programme than in those assigned to 
standard care was accompanied by larger reductions in 
waist circumference and fat mass in all analyses 
(table 2). Table 3 shows changes in insulin, glucose, 
HbA1c, triglycerides, total cholesterol, HDL and LDL 
cholesterol, and the ratio of total to HDL cholesterol 
over 12 months. Participants in the commercial 
programme had sig niﬁ cantly greater improvements  in 
insulin and ratio of total to HDL cholesterol than did 
those assigned to standard care. We noted weak 
evidence of improvements in glucose, and HDL and 
LDL cholesterol in the commercial programme group, 
although these diﬀ er ences did not reach signiﬁ  cance 
for all analyses at the 5% level (table 3).
We recorded small reductions in blood pressure in both 
treatment groups; however, the reduction did not diﬀ er 
signiﬁ cantly between groups (table 2). 96 participants in 
the commercial programme and 99 assigned to standard 
care were receiving an antihypertensive drug at baseline. 
During the course of treatment, two participants in the 
commercial programme stopped antihypertensive treat-
ment and two started, whereas one stopped and six 
started in the standard care group.
At 12 months, 328 (42%) participants had withdrawn 
from the trial (ﬁ gure 1). More completed the ﬁ nal 
assessment in the commercial programme group 
(230 [61%]) than in standard care group (214 [54%]), but 
this diﬀ erence was not signiﬁ cant (p=0∙06). Attrition 
diﬀ ered signiﬁ cantly between countries (p<0∙0001), with 
the number of participants not completing higher in the 
UK (150 [64%]) than in Australia (111 [41%]) and Germany 
(67 [25%]). Despite diﬀ erences in completion rates, the 
weight loss in the commercial programme group was 
N Commercial 
programme
Standard care Adjusted diﬀ erence 
(95% CI)*
p value
Insulin (pmol/L)
LOCF 749 –3·89 (0·97) –0·65 (0·95) –2·89 (–5·47 to –0·31) 0·0284
BOCF 749 –3·66 (0·87) –0·45 (0·89) –3·04 (–5·44 to –0·64) 0·0132
Completers 423 –6·15 (1·44) –0·84 (1·67) –5·74 (–9·86 to –1·61) 0·0065
Glucose (mmol/L)
LOCF 760 –0·06 (0·02) 0·01 (0·03) –0·07 (–0·15 to 0·00) 0·0440
BOCF 760 –0·06 (0·02) –0·01 (0·03) –0·05 (–0·11 to 0·01) 0·07
Completers 428 –0·10 (0·03) –0·02 (0·05) –0·09 (–0·19 to 0·01) 0·08
HbA1C (%)
LOCF 757 –0·08 (0·01) –0·05 (0·01) –0·02 (–0·05 to 0·01) 0·14
BOCF 757 –0·07 (0·01) –0·05 (0·01) –0·02 (–0·04 to 0·01) 0·28
Completers 248 –0·18 (0·03) –0·16 (0·03) 0·00 (–0·08 to 0·07) 0·96
Triglycerides (mmol/L)
LOCF 760 –0·09 (0·03) –0·06 (0·03) –0·03 (–0·10 to 0·04) 0·41
BOCF 760 –0·05 (0·02) –0·05 (0·03) 0·00 (–0·07 to 0·06) 0·92
Completers 429 –0·09 (0·04) –0·10 (0·05) –0·01 (–0·12 to 0·09) 0·80
Cholesterol (mmol/L)
LOCF 760 0·00 (0·04) 0·03 (0·03) –0·04 (–0·13 to 0·05) 0·40
BOCF 760 0·01 (0·03) 0·07 (0·03) –0·07 (–0·14 to 0·01) 0·09
Completers 430 0·01 (0·05) 0·13 (0·05) –0·11 (–0·24 to 0·02) 0·09
LDL cholesterol (mmol/L)
LOCF 758 –0·01 (0·03) 0·02 (0·03) –0·05 (–0·13 to 0·03) 0·22
BOCF 758 –0·01 (0·03) 0·06 (0·02) –0·09 (–0·15 to –0·02) 0·0100
Completers 428 –0·02 (0·04) 0·11 (0·04) –0·13 (–0·24 to –0·02) 0·0222
HDL cholesterol (mmol/L)
LOCF 760 0·06 (0·01) 0·04 (0·01) 0·03 (0·00 to 0·06) 0·08
BOCF 760 0·07 (0·01) 0·04 (0·01) 0·03 (0·01 to 0·06) 0·0051
Completers 428 0·12 (0·02) 0·07 (0·02) 0·05 (0·01 to 0·09) 0·0148
Total cholesterol:HDL
LOCF 759 –0·18 (0·03) –0·11 (0·03) –0·09 (–0·17 to –0·01) 0·0270
BOCF 759 –0·17 (0·03) –0·07 (0·02) –0·12 (–0·18 to –0·05) 0·0008
Completers 428 –0·29 (0·04) –0·13 (0·05) –0·17 (–0·28 to –0·06) 0·0021
LOCF=last observation carried forward. BOCF=baseline observation carried forward. HbA1c=glycated haemoglobin. 
*Adjusted for baseline observation and country. 
Table 3: Changes in biomarkers of cardiovascular disease risk (mean; SE) between baseline and 
12 months by treatment group (with analysis by LOCF, BOCF, and in those who completed the 
12-month assessment)
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signiﬁ cantly greater than in the standard care group in 
each country in all analyses (data not shown).
Participants who completed the 12-month assessment 
were signiﬁ cantly older at baseline (mean 50∙2 years 
[SD 12∙5]) than were those who did not (43∙6 years 
[12∙4]; p<0∙0001). We recorded no signiﬁ cant eﬀ ect of 
sex, baseline weight, or diabetes status on whether 
individuals completed the 12-month assessment (data 
not shown).
Participants attending assessment visits for standard 
care reported a mean of one appointment per month 
with their health-care provider, whereas those in the 
commercial programme attended a mean of three 
meetings per month in the UK and Australia and two 
meetings per month in Germany (webappendix p 1).
No participant reported any serious adverse events 
attributable to weight loss or trial participation during 
the study.
Discussion  
This trial provides important data to inform weight 
management interventions in primary care. Participants 
referred to a community-based commercial provider lost 
more than twice as much weight during 12 months as did 
those who received standard care, even in the most 
conservative analyses (BOCF). The similar weight losses 
achieved in Australia, Germany, and the UK imply that 
this commercial programme, in partnership with primary 
care providers, is a robust intervention that is generalisable 
to other economically developed countries. These results 
are broadly similar to previous investigations of the com-
mer cial programme compared with other community-
based programmes or self-help treatments.7,8
The greater weight loss in participants assigned to the 
commercial programme was accompanied by greater 
reductions in waist circumference and fat mass than in 
participants assigned to standard care, which would be 
expected to lead to a reduction in the risk for type 2 
diabetes and cardiovascular disease.15,16 We also detected a 
suggestion of greater improvements in glucose and lipid 
metabolism in participants in the commercial programme 
group, although these diﬀ erences were not signiﬁ cant in 
all analyses. Measured changes in blood pressure were 
small, although a quarter of participants were receiving 
antihypertensive drugs at the beginning of the study, 
which could have masked any improvements, and the 
remainder had normal blood pressure at baseline. 
Reductions in blood pressure during weight loss are 
mainly recorded in patients with hypertension, and less 
so in participants with normal blood pressure.17–19 These 
modest changes relative to other clinical trials of weight 
loss interventions are probably indicative of the lower 
BMI entry criteria of this study and the lower prevalence 
of comorbid risk factors.7,8
Although mean weight loss in the standard care group 
was lower than that in commercial programme partici-
pants, a quarter of all patients randomly assigned to 
standard care lost 5% or more bodyweight during 
12 months. This ﬁ nding shows the capability of primary 
care professionals to deliver advice and support to enable 
patients to lose weight over 1 year. The delivery of 
standard care programmes diﬀ ered between countries 
but was based on similar principles, as expounded in 
national treatment guidelines. The speciﬁ cs of standard 
care also diﬀ ered both between and within countries, 
although participants in standard care and attending 
assessment visits reported on average one session per 
month with a primary care provider. This level of contact 
in participating practices is probably higher than in 
standard care nationally,20 and could be indicative of 
either the eﬀ ect of the trial on weight management 
services in these practices or a characteristic of 
participants who remained in the study. 
Weight loss in the standard care group in this trial 
can be compared with that from an audit of the Counter-
weight programme.21 The Counterweight programme 
provides intensive training and support for staﬀ 
delivering weight loss treatment in primary care and 
recommends at least six appointments or group 
sessions in the ﬁ rst 3 months, with follow-up appoint-
ments every 3 months. After 12 months, mean weight 
loss was 3∙0 kg (SE 0·3) in people who completed the 
Counterweight programme compared with 3∙3 kg (0·3) 
in those who completed our study. Drop-out rates were 
also similar, with 45% completing the Counter weight 
programme and 54% completing stan dard care in our 
study. Further research is needed to identify whether 
weight loss is directly attributable to any speciﬁ c weight 
management support provided, a result of personal 
actions arising from increased awareness of obesity and 
motivation to lose weight, or the accountability provided 
by regular follow-up.
By contrast with previous studies of commercial weight 
loss programmes in which participants were self-
referred, this study examined a partnership model, with 
partici pants who were likely to beneﬁ t from early 
intervention for weight loss identiﬁ ed and referred by a 
health professional. This study used one example of a 
commercial provider of weight loss treatment. A trial 
that compared a range of self-help programmes (meal 
replacements, commercial weight loss groups, and diet 
books) showed that over 6 months all diets resulted in 
clinically meaningful weight loss (4∙9–7∙3%) compared 
with no diet (0∙6%), with no signiﬁ cant diﬀ erences 
between diets.8 Findings from two randomised controlled 
trials in the USA showed that self-selected participants 
randomly assigned to free participation in the Jenny 
Craig programme and free-of-charge prepackaged foods 
lost signiﬁ cantly more weight than did those referred to 
usual care over 12 months (mean weight loss 6∙6 kg 
[SE 1·8] vs 0∙7 kg [0∙9]; p<0∙01)9 and 24 months (mean 
7∙4 kg [95% CI 6∙1–8∙7] vs 2∙0 kg [1∙2–3∙6]; p<0∙001).11 
These studies suggest that other commercial providers 
working in partnership with primary care providers 
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could also oﬀ er eﬀ ective treatment options, but these 
programmes need to be assessed in a primary health-
care context.
Weight loss reported with more intensive lifestyle 
interventions, such as the Diabetes Prevention Program3 
(5∙6 kg over an average of 2∙8 years) and the Look Ahead 
Study22 (mean 8∙6 kg [SE 0·2] in the ﬁ rst year), was 
greater than that recorded in our study. However, the 
eﬀ ectiveness of such programmes when delivered in 
routine clinical practice, at large scale, and with limited 
resources has not been assessed. Some commercial 
programmes, such as that used in this study, use many 
of the techniques that are used in more intensive 
behavioural treatments delivered by health professionals, 
such as self-monitoring, goal setting, nutritional advice 
(reduced energy, low-fat diets) and exercise education, 
problem solving, stimulus control, and relapse 
prevention.23 Although both commercial programme 
and usual care interventions are based on individual-
level behaviour change, commercial approaches are 
delivered in larger groups by community members and 
are likely to be less expensive than usual care. The large 
group and standardised format of commercial 
programmes could dilute treatment eﬀ ects that are 
recorded in one-to-one and small closed group 
interventions, but could be beneﬁ cial in primary care 
because this format oﬀ ers opportunities for frequent 
contact and regular weighing (standard care participants 
attended one appointment per month on average, and 
participants in the commercial programme attended 
three meetings per month in Australia and the UK and 
two meetings in Germany). The peer-support element of 
group treatment might also be beneﬁ cial for some 
people,24 although for interventions delivered by a range 
of health-care professionals, individual therapy produced 
greater weight loss than did group-based treatment.25 
Further research will examine the relative cost-
eﬀ ectiveness of diﬀ erent treatment approaches.
By contrast with most other weight loss trials 
we included only individuals with overweight and 
moderate obesity (BMI 27–35 kg/m²), to study a 
population with a limited severity of comorbidities and 
at low risk of treatment complications, who are suited to 
a commercial weight loss programme setting. The 
results clearly show that in these selected participants, 
referral to a commercial weight loss programme provider 
is eﬀ ective and safe. Most participants were women. 
This gender bias is common in studies of weight loss in 
primary care,21,26,27 and further research should consider 
whether it results from diﬀ erences in willingness to 
participate in weight loss interventions, gender 
diﬀ erences in general attendance at the GP surgery, or 
diﬀ erences in referral practices.
As with many other clinical obesity trials, the drop-out 
rate was high; however, this rate was anticipated in the 
sample size calculations. Moreover, the ﬁ nding of 
greater weight loss in participants referred to the 
commercial programme was consistent across both 
conservative and liberal analysis protocols, and across 
countries with diﬀ erent attrition rates. Drop-out was 
particularly high in the UK, perhaps because of 
diﬃ  culties in scheduling of follow-up appointments in 
routine clinical practice, which did not occur in the 
specialist research facilities. Additionally, the diverse 
sites, both within and between countries, made 
introduction of a consistent model of standard care 
impractical. The variability recorded in weight loss in 
the standard care group was correspondingly greater 
than in the commercial programme group. However, 
this ﬁ nding probably indicates the diversity of routine 
weight management practices in diﬀ erent health-care 
settings and systems. Participation in the trial and the 
ﬁ ve follow-up assessments, at which participants were 
weighed, might have increased the total weight loss 
recorded in both groups, by enhancing motivation to 
lose weight. However, participation would not aﬀ ect the 
diﬀ erence between the treatments in this randomised 
controlled trial.
 Obesity and its associated comorbidities demand early 
intervention, but the high and rising prevalence of 
obesity puts pressure on scarce health-care resources. 
Data from our study suggest that referral of selected 
participants by a primary health-care professional to a 
commercial weight loss programme that provides 
regular weighing, advice about diet and physical activity, 
motivation, and group support can oﬀ er a clinically 
useful early intervention for weight management in 
overweight and obese people that can be delivered at 
large scale (panel). Further research is needed to examine 
long-term weight loss maintenance, together with a 
formal analysis of cost-eﬀ ectiveness.
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